加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.8753
+US$0.0184 · +2.15%
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
常规交易时段
US$0.8754
+US$0.0185 · +2.16%
盘中时间采用ET。市场数据可能有所延迟。
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
日内区间
当前US$0.8754
52周区间
当前US$0.8754
盘中时间采用ET。市场数据可能有所延迟。
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
日内区间
当前US$0.8754
52周区间
当前US$0.8754
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | — | 23.5万 USD | — |
| 毛利 | — | — | — | −23.5万 USD | — |
| 研究与开发 | 3718.7万 USD | 4167.6万 USD | 3719.6万 USD | 3032.4万 USD | 1857.2万 USD |
| 销售、一般及管理费用 | 1061.2万 USD | 1229万 USD | 1352.8万 USD | 1322.7万 USD | 1002.6万 USD |
| 营业费用 | 4779.9万 USD | 5396.6万 USD | 5072.4万 USD | 4331.6万 USD | 2859.8万 USD |
| 利息收入 | — | — | 2480.5万 USD | 2221.7万 USD | 1744.7万 USD |
| 利息支出 | 1.3万 USD | 2.5万 USD | 2.7万 USD | 2.8万 USD | 89.3万 USD |
| 折旧和摊销 | 22.8万 USD | 26.6万 USD | 25.2万 USD | 23.5万 USD | 9.3万 USD |
| 营业利润 | −4779.9万 USD | −5396.6万 USD | −5072.4万 USD | −4355.1万 USD | −2859.8万 USD |
| 净利润 | −2348.7万 USD | −3397.1万 USD | −2578.8万 USD | 75.7万 USD | −1171.6万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI251.76万0.00%2.3万亿 USD0.03%US$380.81-0.20%
Vanguard Extended Market ETFVXF95.16万0.00%954亿 USD0.05%US$231.92-0.69%
iShares Micro-Cap ETFIWC22.34万0.02%13.17亿 USD0.60%US$180.26-0.77%
iShares Neuroscience and Healthcare ETFIBRN7284.510.12%635.78万 USD0.47%US$31.430.00%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCiShares Neuroscience and Healthcare ETFIBRNAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
